Company Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer.
It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19.
The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | May 8, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 620 Memorial Drive Cambridge, Massachusetts United States | |
| Website | https://www.evelobio.com |
Stock Details
| Ticker Symbol | EVLO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001694665 |
| CUSIP Number | 299734103 |
| ISIN Number | US2997342025 |
| Employer ID | 46-5594527 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer & Director |
| Douglas Maslin | Senior Director & Immunology Clinical Lead |
| Dr. Andrea Itano Ph.D. | Head of Research |
| Dr. Chun Zhang Ph.D. | Chief Technical Operations & Quality Officer |
| Dr. Duncan McHale M.D., MBBS, Ph.D. | Chief Medical Officer |
| Dr. Mark Bodmer Ph.D. | Chief Scientific Officer and President of Research & Development |
| Jessica Cotrone | Vice President & Head of Communications |
| Leslie Wardwell-Scott Ph.D. | Vice President and Head of Corporate Development & Strategic Integration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 26, 2024 | 15-12G | Filing |
| Jan 26, 2024 | S-8 POS | Filing |
| Jan 26, 2024 | S-8 POS | Filing |
| Jan 26, 2024 | POS AM | Filing |
| Jan 26, 2024 | 8-K | Current Report |
| Dec 27, 2023 | 25-NSE | Filing |
| Dec 12, 2023 | DEFA14A | Filing |
| Dec 12, 2023 | DEF 14A | Filing |
| Dec 11, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 04, 2023 | 8-K | Current Report |